Skip to main content Accessibility help
×
Home
  • Print publication year: 2015
  • Online publication date: April 2015

Chapter 25 - Biology of human stomach cancer

from Part 5 - Current state of the evolving MMMN cancer progression models of cancer

References

1. Correa P, Chen V, eds. 1994. Trends in Cancer Incidence and Mortality: Gastric Cancer. New York: Cold Spring Harbor Laboratory Press.
2. Crew KD, Neugut AI. 2006. Epidemiology of gastric cancer. World J Gastroenterol 12:354–62.
3. Marugame T, Dongmei Q. 2007. Comparison of time trends in stomach cancer incidence (1973–1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. Jpn J Clin Oncol 37:242–3.
4. Parker SL, Tong T, Bolden S, Wingo PA. 1996. Cancer statistics, 1996. CA Cancer J Clin 46:5–28.
5. Correa P, Houghton J. 2007. Carcinogenesis of Helicobacter pylori. Gastroenterology 133:659–72.
6. Uemura N, Okamoto S, Yamamoto S, et al. 2001. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–9.
7. Fukase K, Kato M, Kikuchi S, et al. 2008. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372:392–7.
8. Elsborg L, Mosbech J. 1979. Pernicious anaemia as a risk factor in gastric cancer. Acta Medica Scandinavica 206:315–8.
9. Joossens JV, Hill MJ, Elliott P, et al. 1996. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol 25:494–504.
10. Rowlands DC, Ito M, Mangham DC, et al. 1993. Epstein–Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas. Br J Cancer 68:1014–19.
11. Lauren P. 1965. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31–49.
12. Correa P, Shiao YH. 1994. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54:1941–3.
13. de Vries AC, van Grieken NC, Looman CW, et al. 2008. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134:945–52.
14. Oota K, Sobin LH. 1977. Histological Typing Gastric and Esophageal Carcinogenesis. Geneva: World Health Organization.
15. Ming S-C. 1977. Gastric carcinoma: a pathobiological classification. Cancer 39:2475–85.
16. Borrmann R. 1926. Gushwulste de Magens and Duodenums. In Henke F, Lubarsh O, eds. Handbuch der Speziellen Pathologischen Anatomie und Histologie. Berlin: Springer, p. 865.
17. Dixon MF, Martin JG, Sue-Ling HM, et al. 1994. Goseki grading in gastric cancer: comparison with existing systems of grading and its reproducibility. Histopathology 25:309–16.
18. Kennedy BJ. 1987. The unified international gastric cancer staging classification. Gastroenterology 1–13.
19. Hirota T, Ming SC, Itabashi M. 1993. Pathology of early gastric cancer. In Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, eds. Gastric Cancer. Tokyo, New York: Springer-Verlag; pp. 66–86.
20. El-Omar EM, Carrington M, Chow WH, et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402.
21. El-Omar EM, Rabkin CS, Gammon MD, et al. 2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124:1193–201.
22. Machado JC, Figueiredo C, Canedo P, et al. 2003. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 125:364–71.
23. Hold GL, Rabkin CS, Chow WH, et al. 2007. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132:905–12.
24. Lee JE, Lowy AM, Thompson WA, et al. 1996. Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology 111:426–32.
25. Sakai T, Aoyama N, Satonaka K, et al. 1999. HLA-DQB1 locus and the development of atrophic gastritis with Helicobacter pylori infection. J Gastroenterol 34 Suppl 11:24–7.
26. Aird I, Bentall HH, Roberts JA. 1953. A relationship between cancer of stomach and the ABO blood groups. BMJ 1:799–801.
27. Buckwalter JA, Wohlwend CB, Colter DC, Tidrick RT, Knowler LA. 1957. The association of the ABO blood groups to gastric carcinoma. Surg Gynecol Obstet 104:176–9.
28. Boren T, Falk P, Roth KA, Larson G, Normark S. 1993. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 262:1892–5.
29. Carvalho F, Seruca R, David L, et al. 1997. MUC1 gene polymorphism and gastric cancer – an epidemiological study. Glycoconj J 14:107–11.
30. Sheu MJ, Yang HB, Sheu BS, et al. 2006. Erythrocyte Lewis (A+B–) host phenotype is a factor with familial clustering for increased risk of Helicobacter pylori-related non-cardiac gastric cancer. J Gastroenterol Hepatol 21:1054–8.
31. Park GT, Lee OY, Kwon SJ, et al. 2003. Analysis of CYP2E1 polymorphism for the determination of genetic susceptibility to gastric cancer in Koreans. J Gastroenterol Hepatol 18:1257–63.
32. Miao X, Zhang X, Zhang L, et al. 2006. Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer. Gastroenterology 131:420–7.
33. La Vecchia C, Negri E, Franceschi S, Gentile A. 1992. Family history and the risk of stomach and colorectal cancer. Cancer 70:50–5.
34. Videbaek A, Mosbech J. 1954. The aetiology of gastric carcinoma elucidated by a study of 302 pedigrees. Acta Medica Scandinavica 149:137–59.
35. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. 1994. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600–8.
36. Antommarchi F. 1825. Les derniers moments de Napoleon, en compement du memorial de Sainte-Helene, 1st edn. Brusselles, Belgium: H Tarlier.
37. Kubba AK, Young M. 1999. The Napoleonic cancer gene? J Med Biogr 7:175–81.
38. Lugli A, Zlobec I, Singer G, et al. 2007. Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nat Clin Pract Gastroenterol Hepatol 4:52–7.
39. Hemminki K, Jiang Y. 2002. Familial and second gastric carcinomas: a nationwide epidemiologic study from Sweden. Cancer 94:1157–65.
40. Zanghieri G, Di Gregorio C, Sacchetti C, et al. 1990. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 66:2047–51.
41. Palli D, Galli M, Caporaso NE, et al. 1994. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 3:15–18.
42. Gorer PA. 1938. Genetic interpretation of studies on cancer in twins. Annals Eugenics 8:219.
43. Lee FI. 1971. Carcinoma of the gastric antrum in identical twins. Postgrad Med J 47:622–4.
44. Aoki M, Yamamoto K, Noshiro H, et al. 2005. A full genome scan for gastric cancer. J Med Genet 42:83–7.
45. Guilford P, Hopkins J, Harraway J, et al. 1998. E-cadherin germline mutations in familial gastric cancer. Nature 392:402–5.
46. Blair V, Martin I, Shaw D, et al. 2006. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 4:262–75.
47. Caldas C, Carneiro F, Lynch HT, et al. 1999. Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–80.
48. Brooks-Wilson AR, Kaurah P, Suriano G, et al. 2004. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41:508–17.
49. Lynch HT, Grady W, Suriano G, Huntsman D. 2005. Gastric cancer: new genetic developments. J Surg Oncol 90:114–33.
50. Kaurah P, MacMillan A, Boyd N, et al. 2007. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:2360–72.
51. Norton JA, Ham CM, Van Dam J, et al. 2007. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–9.
52. Ascano JJ, Frierson H, Jr., Moskaluk CA, et al. 2001. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 14:942–9.
53. Stone J, Bevan S, Cunningham D, et al. 1999. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer 79:1935–7.
54. Lynch HT, Smyrk TC, Watson P, et al. 1993. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104:1535–49.
55. Kinzler KW, Vogelstein B. 1996. Lessons from hereditary colorectal cancer. Cell 87:159–70.
56. Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Jarvinen HJ. 1997. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 74:551–5.
57. Lynch HT, Krush AJ. 1971. Cancer family “G” revisited: 1895–1970. Cancer 27:1505–11.
58. Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al. 2002. No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 37:574–7.
59. Li FP, Fraumeni JF, Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71:747–52.
60. Varley JM, McGown G, Thorncroft M, et al. 1995. An extended Li–Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 32:942–5.
61. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. 1997. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150:1–13.
62. Lindor NM, Greene MH. 1998. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 90:1039–71.
63. Hofgartner WT, Thorp M, Ramus MW, et al. 1999. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 94:2275–81.
64. Park WS, Moon YW, Yang YM, et al. 1998. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol 13:601–4.
65. Groden J, Thliveris A, Samowitz W, et al. 1991. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589–600.
66. Offerhaus GJ, Giardiello FM, Krush AJ, et al. 1992. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 102:1980–2.
67. Jones S, Emmerson P, Maynard J, et al. 2002. Biallelic germline mutations in MYH predispose to multiple colorectal adenoma and somatic G:C–>T:A mutations. Hum Mol Genet 11:2961–7.
68. Kim CJ, Cho YG, Park CH, et al. 2004. Genetic alterations of the MYH gene in gastric cancer. Oncogene 23:6820–2.
69. Zhang Y, Liu X, Fan Y, et al. 2006. Germline mutations and polymorphic variants in MMR, E-cadherin and MYH genes associated with familial gastric cancer in Jiangsu of China. Int J Cancer 119:2592–6.
70. Hizawa K, Iida M, Yao T, Aoyagi K, Fujishima M. 1997. Juvenile polyposis of the stomach: clinicopathological features and its malignant potential. J Clin Pathol 50:771–4.
71. Maimon SN, Zinninger MM. 1953. Familial gastric cancer. Gastroenterology 25:139–52; discussion, 53–5.
72. Woolf CM, Isaacson EA. 1961. An analysis of 5 “stomach cancer families” in the state of Utah. Cancer 14:1005–16.
73. Oliveira C, Seruca R, Carneiro F. 2006. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 14:21–33.
74. Dellavecchia C, Guala A, Olivieri C, et al. 1999. Early onset of gastric carcinoma and constitutional deletion of 18p. Cancer Genet Cytogenet 113:96–9.
75. Seruca R, Castedo S, Correia C, et al. 1993. Cytogenetic findings in eleven gastric carcinomas. Cancer Genet Cytogenet 68:42–8.
76. Gayther SA, Gorringe KL, Ramus SJ, et al. 1998. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58:4086–9.
77. Massad M, Uthman S, Obeid S, Majjar F. 1990. Ataxia-telangiectasia and stomach cancer. Am J Gastroenterol 85:630–1.
78. Lee JH, Han SU, Cho H, et al. 2000. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947–53.
79. McDonald SA, Greaves LC, Gutierrez-Gonzalez L, et al. 2008. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 134:500–10.
80. Sasaki O, Soejima K, Korenaga D, Haraguchi Y. 1999. Comparison of the intratumor DNA ploidy distribution pattern between differentiated and undifferentiated gastric carcinoma. Anal Quant Cytol Histol 21:161–5.
81. Panani AD, Ferti A, Malliaros S, Raptis S. 1995. Cytogenetic study of 11 gastric adenocarcinomas. Cancer Genet Cytogenet 81:169–72.
82. Varis A, van Rees B, Weterman M, et al. 2003. DNA copy number changes in young gastric cancer patients with special reference to chromosome 19. Br J Cancer 88:1914–19.
83. El-Rifai W, Harper JC, Cummings OW, et al. 1998. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res 58:34–7.
84. Moskaluk CA, Hu J, Perlman EJ. 1998. Comparative genomic hybridization of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer 22:305–11.
85. Kimura Y, Noguchi T, Kawahara K, et al. 2004. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17:1328–37.
86. Hidaka S, Yasutake T, Kondo M, et al. 2003. Frequent gains of 20q and losses of 18q are associated with lymph node metastasis in intestinal-type gastric cancer. Anticancer Res 23:3353–7.
87. Yustein AS, Harper JC, Petroni GR, et al. 1999. Allelotype of gastric adenocarcinoma. Cancer Res 59:1437–41.
88. Sano T, Tsujino T, Yoshida K, et al. 1991. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. Cancer Res 51:2926–31.
89. Uchino S, Tsuda H, Noguchi M, et al. 1992. Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 52:3099–102.
90. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. 1994. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology 106:1584–8.
91. Schneider BG, Pulitzer DR, Brown RD, et al. 1995. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer 13:263–71.
92. Rumpel CA, Powell SM, Moskaluk CA. 1999. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 154:1329–34.
93. Iacopetta BJ, Soong R, House AK, Hamelin R. 1999. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes. J Pathol 187:428–32.
94. dos Santos NR, Seruca R, Constancia M, Seixas M, Sobrinho-Simoes M. 1996. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 110:38–44.
95. Halling KC, Harper J, Moskaluk CA, et al. 1999. Origin of microsatellite instability in gastric cancer. Am J Pathol 155:205–11.
96. Fleisher AS, Esteller M, Wang S, et al. 1999. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59:1090–5.
97. Leung SY, Yuen ST, Chung LP, et al. 1999. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59:159–64.
98. Suzuki H, Itoh F, Toyota M, et al. 1999. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer 83:309–13.
99. Hirata T, Yamamoto H, Taniguchi H, et al. 2007. Characterization of the immune escape phenotype of human gastric cancers with and without high-frequency microsatellite instability. J Pathol 211:516–23.
100. Strickler JG, Zheng J, Shu Q, et al. 1994. P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 54:4750–5.
101. Ottini L, Palli D, Falchetti M, et al. 1997. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res 57:4523–9.
102. Oliveira C, Seruca R, Seixas M, Sobrinho-Simoes M. 1998. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different “target genes”: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol 153:1211–19.
103. Wu MS, Lee CW, Shun CT, et al. 1998. Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res 58:1494–7.
104. Yamamoto H, Perez-Piteira J, Yoshida T, et al. 1999. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 116:1348–57.
105. Ottini L, Falchetti M, D'Amico C, et al. 1998. Mutations at coding mononucleotide repeats in gastric cancer with the microsatellite mutator phenotype. Oncogene 16:2767–72.
106. Myeroff LL, Parsons R, Kim SJ, et al. 1995. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 55:5545–7.
107. Park K, Kim SJ, Bang YJ, et al. 1994. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proce Natl Acad Sci USA 91:8772–6.
108. Kang SH, Bang YJ, Im YH, et al. 1999. Transcriptional repression of the transforming growth factor-beta type I receptor gene by DNA methylation results in the development of TGF-beta resistance in human gastric cancer. Oncogene 18:7280–6.
109. Mori Y, Sato F, Selaru FM, et al. 2002. Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res 62:3641–5.
110. Yamamoto H, Sawai H, Perucho M. 1997. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 57:4420–6.
111. Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M. 1999. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 59:2034–7.
112. Souza RF, Appel R, Yin J, et al. 1996. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 14:255–7.
113. Souza RF, Yin J, Smolinski KN, et al. 1997. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res 57:2350–3.
114. Yin J, Kong D, Wang S, et al. 1997. Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas. Hum Mutat 10:474–8.
115. Luqmani Y, Bennett C, Paterson I, et al. 1989. Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 44:806–12.
116. Henry JA, Bennett MK, Piggott NH, et al. 1991. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 64:677–82.
117. Muller W, Borchard F. 1993. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J Pathol 171:263–9.
118. Wu MS, Shun CT, Wang HP, et al. 1998. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res 89:278–82.
119. Lefebvre O, Chenard MP, Masson R, et al. 1996. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 274:259–62.
120. Machado JC, Carneiro F, Blin N, Sobrinho-Simoes M. 1996. Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa. Eur J Cancer Prev 5:169–79.
121. Nogueira AM, Machado JC, Carneiro F, et al. 1999. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol 187:541–8.
122. Sakata K, Tamura G, Nishizuka S, et al. 1997. Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer 18:318–21.
123. Nishizuka S, Tamura G, Terashima M, Satodate R. 1998. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J Pathol 185:38–43.
124. Calnan DP, Westley BR, May FE, et al. 1999. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 188:312–17.
125. Beckler AD, Roche JK, Harper JC, et al. 2003. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer 98:2184–91.
126. Sankpal NV, Mayo MW, Powell SM. 2005. Transcriptional repression of TFF1 in gastric epithelial cells by CCAAT/enhancer binding protein-beta. Biochim Biophys Acta 1728:1–10.
127. Sankpal NV, Moskaluk CA, Hampton GM, Powell SM. 2006. Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer. Oncogene 25:643–9.
128. Tebbutt NC, Giraud AS, Inglese M, et al. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8:1089–97.
129. Howlett M, Judd LM, Jenkins B, et al. 2005. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology 129:1005–18.
130. Birchmeier W, Behrens J. 1994. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198:11–26.
131. Mayer B, Johnson JP, Leitl F, et al. 1993. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53:1690–5.
132. Becker KF, Atkinson MJ, Reich U, et al. 1994. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845–52.
133. Berx G, Becker KF, Hofler H, van Roy F. 1998. Mutations of the human E-cadherin (CDH1) gene. Hum Mut 12:226–37.
134. Matsui S, Shiozaki H, Inoue M, et al. 1994. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch 424:375–81.
135. Morris LE, Bloom GS, Frierson HF, Jr., Powell SM. 2005. Nucleotide variants within the IQGAP1 gene in diffuse-type gastric cancers. Genes Chromosomes Cancer 42:280–6.
136. Hollstein M, Shomer B, Greenblatt M, et al. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141–6.
137. Hurlimann J, Saraga EP. 1994. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 18:1247–53.
138. Gabbert HE, Muller W, Schneiders A, Meier S, Hommel G. 1995. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76:720–6.
139. Gschwind A, Fischer OM, Ullrich A. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4:361–70.
140. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501.
141. Samuels Y, Wang Z, Bardelli A, et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554.
142. Li VS, Wong CW, Chan TL, et al. 2005. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 5:29.
143. Kang MJ, Ryu BK, Lee MG, et al. 2008. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 135:2030–42, 42 e1–3.
144. Sakakura C, Hagiwara A, Yasuoka R, et al. 2001. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824–31.
145. Wang Z, Shen D, Parsons DW, et al. 2004. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304:1164–6.
146. Lee JW, Jeong EG, Lee SH, et al. 2007. Mutational analysis of PTPRT phosphatase domains in common human cancers. APMIS 115:47–51.
147. Kastury K, Baffa R, Druck T, et al. 1996. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56:978–83.
148. Ohta M, Inoue H, Cotticelli MG, et al. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587–97.
149. Baffa R, Veronese ML, Santoro R, et al. 1998. Loss of FHIT expression in gastric carcinoma. Cancer Res 58:4708–14.
150. Gemma A, Hagiwara K, Ke Y, et al. 1997. FHIT mutations in human primary gastric cancer. Cancer Res 57:1435–7.
151. Nakajima M, Sawada H, Yamada Y, et al. 1999. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85:1894–902.
152. Kuniyasu H, Yasui W, Kitadai Y, et al. 1992. Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Comm 189:227–32.
153. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E. 1993. Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55:72–5.
154. Hara T, Ooi A, Kobayashi M, et al. 1998. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78:1143–53.
155. Taniguchi K, Yonemura Y, Nojima N, et al. 1998. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82:2112–22.
156. Tsugawa K, Yonemura Y, Hirono Y, et al. 1998. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55:475–81.
157. Koshiba M, Ogawa O, Habuchi T, et al. 1993. Infrequent ras mutation in human stomach cancers. Jpn J Cancer Res 84:163–7.
158. Lee KH, Lee JS, Suh C, et al. 1995. Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer: an analysis of 140 cases. Cancer 75:2794–801.
159. Tahara E. 1995. Molecular biology of gastric cancer. World J Surg 19:484–8; discussion, 489–90.
160. Inoue T, Chung YS, Yashiro M, et al. 1997. Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 88:152–9.
161. Kondo S, Shinomura Y, Kanayama S, et al. 1995. Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem Biophys Res Comm 210:960–5.
162. Taha AS, Curry GW, Morton R, Park RH, Beattie AD. 1996. Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. Am J Gastroenterol 91:1407–9.
163. Yasunaga Y, Shinomura Y, Kanayama S, et al. 1996. Increased production of interleukin 1 beta and hepatocyte growth factor may contribute to foveolar hyperplasia in enlarged fold gastritis. Gut 39:787–94.
164. Igaki H, Sasaki H, Tachimori Y, et al. 1995. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 55:3421–3.
165. Barrett MT, Sanchez CA, Galipeau PC, et al. 1996. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13:1867–73.
166. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ. 1997. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 57:2619–22.
167. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R. 1998. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115:1381–6.
168. Toyota M, Ahuja N, Suzuki H, et al. 1999. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59:5438–42.
169. Chi XZ, Yang JO, Lee KY, et al. 2005. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25:8097–107.
170. Ito K, Liu Q, Salto-Tellez M, et al. 2005. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65:7743–50.
171. Sakakura C, Hasegawa K, Miyagawa K, et al. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin Cancer Res 11:6479–88.
172. Tamura G. 2004. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol 19:221–8.
173. Zou B, Chim CS, Zeng H, et al. 2006. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology 131:1835–43.
174. Yu J, Cheng YY, Tao Q, et al. 2009. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136:640–51.
175. Tokunaga A, Onda M, Okuda T, et al. 1995. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75:1418–25.
176. Tahara E, Semba S, Tahara H. 1996. Molecular biological observations in gastric cancer. Semin Oncol 23:307–15.
177. Ueki T, Koji T, Tamiya S, Nakane PK, Tsuneyoshi M. 1995. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma. J Pathol 177:353–61.
178. Yonemura Y, Ninomiya I, Yamaguchi A, et al. 1991. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51:1034–8.
179. Mizutani T, Onda M, Tokunaga A, Yamanaka N, Sugisaki Y. 1993. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 72:2083–8.
180. Uchino S, Tsuda H, Maruyama K, et al. 1993. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 72:3179–84.
181. Bizari L, Borim AA, Leite KR, et al. 2006. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet 165:41–50.
182. Chariyalertsak S, Sugano K, Ohkura H, Mori Y. 1994. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer. Tumour Biol 15:294–303.
183. Tateishi M, Toda T, Minamisono Y, Nagasaki S. 1992. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 49:209–12.
184. Friess H, Fukuda A, Tang WH, et al. 1999. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 23:1010–18.
185. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. 1998. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 4:1071–4.
186. Lee JW, Jeong EG, Soung YH, et al. 2006. Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology 38:312–15.
187. Kondo S, Shinomura Y, Miyazaki Y, et al. 2000. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 60:4328–30.
188. Kuraoka K, Matsumura S, Sanada Y, et al. 2005. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep 14:465–70.
189. Park WS, Lee JH, Shin MS, et al. 2001. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology 121:1219–25.
190. Saito H, Tsujitani S, Oka S, et al. 1999. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 81:484–9.
191. Hachisuka T, Narikiyo M, Yamada Y, et al. 2005. High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol Rep 13:733–7.
192. Kim J, Sohn S, Chae Y, et al. 2007. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 18:1030–6.
193. El-Rifai W, Smith MF, Jr., Li G, et al. 2002. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 62:4061–4.
194. Belkhiri A, Zaika A, Pidkovka N, et al. 2005. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 65:6583–92.
195. Powell SM, Harper JC, Hamilton SR, Robinson CR, Cummings OW. 1997. Inactivation of Smad4 in gastric carcinomas. Cancer Res 57:4221–4.
196. Nagase H, Nakamura Y. 1993. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mut 2:425–34.
197. Ogasawara S, Maesawa C, Tamura G, Satodate R. 1994. Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas. Virchows Arch 424:607–11.
198. Maesawa C, Tamura G, Suzuki Y, et al. 1995. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J Pathol 176:249–58.
199. Powell SM, Cummings OW, Mullen JA, et al. 1996. Characterization of the APC gene in sporadic gastric adenocarcinomas. Oncogene 12:1953–9.
200. Tamura G, Ogasawara S, Nishizuka S, et al. 1996. Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 56:612–15.
201. Park WS, Oh RR, Park JY, et al. 1999. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 59:4257–60.
202. Candidus S, Bischoff P, Becker KF, Hofler H. 1996. No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. Cancer Res 56:49–52.
203. Ramesh S, Nash J, McCulloch PG. 1999. Reduction in membranous expression of beta-catenin and increased cytoplasmic E-cadherin expression predict poor survival in gastric cancer. Br J Cancer 81:1392–7.
204. Kawanishi J, Kato J, Sasaki K, et al. 1995. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 15:1175–81.
205. Tsuji S, Kawano S, Sawaoka H, et al. 1996. Evidence for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 55:179–83.
206. Ma X, Chen K, Huang S, et al. 2005. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 26:1698–705.
207. Ito H, Yonemura Y, Fujita H, et al. 1996. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch 427:487–96.
208. Burgart LJ, Zheng J, Shu Q, Strickler JG, Shibata D. 1995. Somatic mitochondrial mutation in gastric cancer. Am J Pathol 147:1105–11.
209. Hiyama E, Yokoyama T, Tatsumoto N, et al. 1995. Telomerase activity in gastric cancer. Cancer Res 55:3258–62.
210. Wong SC, Yu H, So JB. 2006. Detection of telomerase activity in gastric lavage fluid: a novel method to detect gastric cancer. J Surg Res 131:252–5.
211. Guan XY, Fu SB, Xia JC, et al. 2000. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogen 123:27–34.
212. Hippo Y, Taniguchi H, Tsutsumi S, et al. 2002. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62:233–40.
213. Leung SY, Chen X, Chu KM, et al. 2002. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci USA 99:16203–8.
214. Boussioutas A, Li H, Liu J, et al. 2003. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 63:2569–77.
215. Weiss MM, Kuipers EJ, Postma C, et al. 2004. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 26:307–17.
216. Petrocca F, Visone R, Onelli MR, et al. 2008. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13:272–86.
217. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. 2002. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823–6.
218. Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. 1998. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer 79:256–62.
219. Han S, Kim HY, Park K, et al. 1999. c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer. J Korean Med Sci 14:526–30.
220. Kuwahara A, Katano M, Nakamura M, et al. 1999. New therapeutic strategy for gastric carcinoma: a two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surgical Oncol 72:142–9.
221. Lin WC, Li AF, Chi CW, et al. 1999. Tie-1 protein tyrosine kinase: a novel independent prognostic marker for gastric cancer. Clin Cancer Res 5:1745–51.
222. Maeda K, Kang SM, Onoda N, et al. 1999. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 86:566–71.
223. Takano Y, Kato Y, Masuda M, Ohshima Y, Okayasu I. 1999. Cyclin D2, but not cyclin D1, overexpression closely correlates with gastric cancer progression and prognosis. J Pathol 189:194–200.
224. Ganesh S, Sier CF, Heerding MM, et al. 1996. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77:1035–43.
225. Jang SJ, Park YW, Park MH, et al. 1999. Expression of cell-cycle regulators, cyclin E and p21WAF1/CIP1, potential prognostic markers for gastric cancer. Eur J Surg Oncol 25:157–63.
226. Kwon OJ, Kang HS, Suh JS, et al. 1999. The loss of p27 protein has an independent prognostic significance in gastric cancer. Anticancer Res 19:4215–20.
227. Xiangming C, Hokita S, Natsugoe S, et al. 1999. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 is a predictor of lymph node metastasis in early gastric cancer. Oncology 57:131–7.
228. Zafirellis K, Karameris A, Milingos N, Androulakis G. 2005. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Anticancer Res 25:3629–36.
229. Liu XP, Kawauchi S, Oga A, et al. 2001. Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 39:603–10.
230. Nagahara H, Mimori K, Utsunomiya T, et al. 2005. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 11:6800–6.
231. Nishigaki R, Osaki M, Hiratsuka M, et al. 2005. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 5:3205–13.
232. Cascinu S, Graziano F, Del Ferro E, et al. 1998. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83:1917–22.
233. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. 1999. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 56:253–8.
234. Muguruma K, Nakata B, Hirakawa K, et al. 1998. p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma. Cancer & Chemotherapy 25 Suppl 3:400–3.
235. Nakata B, Muguruma K, Hirakawa K, et al. 1998. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 55:543–7.
236. Kurihara N, Kubota T, Furukawa T, et al. 1999. Chemosensitivity testing of primary tumor cells from gastric cancer patients with liver metastasis can identify effective antitumor drugs. Anticancer Res 19:5155–8.
237. Torii A, Kodera Y, Uesaka K, et al. 1997. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84:133–6.
238. Gofuku J, Shiozaki H, Doki Y, et al. 1998. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 78:1095–101.
239. De Vita F, Orditura M, Galizia G, et al. 1999. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86:1936–43.
240. Han SU, Lee JH, Kim WH, Cho YK, Kim MW. 1999. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23:1176–80.
241. Yoshikawa T, Saitoh M, Tsuburaya A, et al. 1999. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 86:1929–35.
242. Nakata B, Hirakawa-Ys Chung K, Kato Y, et al. 1998. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83:2488–92.
243. Pituch-Noworolska A, Wieckiewicz J, Krzeszowiak A, et al. 1998. Evaluation of circulating tumour cells expressing CD44 variants in the blood of gastric cancer patients by flow cytometry. Anticancer Res 18:3747–52.
244. Chausovsky G, Luchansky M, Figer A, et al. 1999. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer 86:2398–405.
245. Marrelli D, Roviello F, De Stefano A, et al. 1999. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. Oncology 57:55–62.
246. Wu CW, Lin YY, Chen GD, et al. 1999. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 80:483–8.
247. Wu CY, Wu MS, Chiang EP, et al. 2007. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782–9.
248. Poon TC, Sung JJ, Chow SM, et al. 2006. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 130:1858–64.
249. Demetri GD. 2001. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 28:19–26.
250. DeMatteo RP. 2002. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9:831–9.
251. Nakamura K, Yashiro M, Matsuoka T, et al. 2006. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 131:1530–41.
252. Fukaya M, Isohata N, Ohta H, et al. 2006. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology 131:14–29.
253. Abnet CC, Freedman ND, Kamangar F, et al. 2009. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer 100:551–7.
254. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. 1993. Aspirin use and risk of fatal cancer. Cancer Res 53:1322–7.